



## Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9

November 2, 2020

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM ET.

### Conference Call & Webcast Information

When: Monday, November 9, 2020, at 4:30 PM ET

Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)

Conference ID: 6166976

Please join the conference call at least 20 minutes early to register. You can access the live webcast under the [investor relations](#) section of Arena's [website](#). A replay of the event will be archived for 30 days after the call.

### About Arena Pharmaceuticals

[ARENA Pharmaceuticals](#) is a team with a singular purpose – deliver our important medicines to patients.

In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

ARENA - *Care More. Act Differently.*

### Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's position, drive, portfolio, prioritization, financial position, team, and building of the company. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

### Corporate Contacts:

Patrick Malloy

Arena Pharmaceuticals, Inc.

Vice President, Investor Relations & Corporate Communications

[pmalloy@arenapharm.com](mailto:pmalloy@arenapharm.com)

847.987.4878

Megan E. Knight

Arena Pharmaceuticals, Inc.

Director, Investor Relations

[mknight@arenapharm.com](mailto:mknight@arenapharm.com)

858.210.3635



[2020-financial-results-and-provide-corporate-update-on-november-9-301164378.html](https://www.arena-pharm.com/2020-financial-results-and-provide-corporate-update-on-november-9-301164378.html)

SOURCE Arena Pharmaceuticals, Inc.